OUTCOMES OF TRIPLE NEGATIVE BREAST CANCER IN EARLY BREAST CANCER WITH NEO ADJUVANT CHEMOTHERAPY
Genetics and Molecular Research · 07.07.2026
DOI: 10.4238/exxtsn80 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genetics and Molecular Research, online erschienen am 07.07.2026. Verfasst von Bushra Malik und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-SA 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objectives
To determine the outcomes of triple negative breast cancer in early breast cancer with neo adjuvant chemotherapy. Materials and Methods: After approval from the review board, patients were enrolled following written informed consent for voluntary participation. Data were collected from all participants, including detailed physical examination findings and medical history. Demographic variables were noted. Patients received protocol-based treatment with either an immunotherapy-based regimen or standard neoadjuvant anthracycline-based chemotherapy every three weeks for three cycles, along with standard supportive medications. Following treatment completion, surgery was performed and specimens were sent for histopathological evaluation. Data were recorded in a questionnaire and analyzed with SPSS 26.
Results
The majority of patients were between 31 and 40 years old, with a mean age of 42.69 ± 9.71 years and a mean BMI of 22.48 ± 4.12 kg/m². Illiteracy, housewife position, urban living, right-sided sickness, and middling socioeconomic level were more prevalent. While there was no discernible correlation between treatment response and age, breast laterality, or BMI, nearly half obtained complete remission.
Conclusion
It was concluded that neoadjuvant chemotherapy plays a crucial role in the treatment of early triple-negative breast cancer, and that the best indicator of enhanced survival is pathological full response. To improve therapy response and optimize treatment techniques, more research is advised.
Zitieren
APA
Malik, B., Tariq, M., Hassan, A., Bibi, M., Shaheen, K., & Sabir, I. (2026). OUTCOMES OF TRIPLE NEGATIVE BREAST CANCER IN EARLY BREAST CANCER WITH NEO ADJUVANT CHEMOTHERAPY. Genetics and Molecular Research. https://doi.org/10.4238/exxtsn80
Vancouver
Malik B, Tariq M, Hassan A, Bibi M, Shaheen K, Sabir I. OUTCOMES OF TRIPLE NEGATIVE BREAST CANCER IN EARLY BREAST CANCER WITH NEO ADJUVANT CHEMOTHERAPY. Genetics and Molecular Research. 2026. doi:10.4238/exxtsn80
BibTeX
@article{Malik2026,
author = {Malik, Bushra and Tariq, Muhammad and Hassan, Asiya and Bibi, Maryam and Shaheen, Kiran and Sabir, Irum},
title = {OUTCOMES OF TRIPLE NEGATIVE BREAST CANCER IN EARLY BREAST CANCER WITH NEO ADJUVANT CHEMOTHERAPY},
journal = {Genetics and Molecular Research},
year = {2026},
doi = {10.4238/exxtsn80}
}
EUVIMED